Cases & Deals

Ysios Capital and strategic investor invest in Kala Pharmaceuticals

Client(s) Ysios Capital Partners and strategic investor

Jones Day represented Ysios Capital Partners and a strategic investor in connection with their investment in a $22.5 million private placement of Series B Preferred Stock by Kala Pharmaceuticals, Inc., a leading developer of innovative products that enhance penetration of therapeutic agents into ocular tissue based on Kala’s proprietary Mucus Penetrating Particle technology.